TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024 16:15 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024 08:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024 16:05 ET
|
TransCode Therapeutics, Inc.
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024 08:30 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024 16:45 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics closes public offering
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024 13:27 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024 16:05 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024 08:00 ET
|
TransCode Therapeutics, Inc.
TransCode Announces Reverse Stock Split
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024 08:05 ET
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders of TransCode Therapeutics, Inc.